FPF
BCRX icon

FNY Partners Fund’s BioCryst Pharmaceuticals BCRX Stock Holding History

FNY Partners Fund’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,000
Closed -$20K – 438
2017
Q3 		$20K Hold
4,000
– – ﹤0.01% 372
2017
Q2 		$22K Buy
+4,000
New +$24.4K 0.01% 335

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

FNY Partners Fund's BCRX Position: Q4 2017 in Review

FNY Partners Fund sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2017, closing a stake of 4,000 shares — an estimated $20K sold.

FNY Partners Fund first reported a position in BCRX in Q2 2017 and held it in 2 quarters. The position peaked at $22K in Q2 2017. 116 funds tracked by Wall St. Rank hold BCRX as of Q4 2017.

  • FNY Partners Fund reported no remaining BioCryst Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • FNY Partners Fund sold 4,000 BioCryst Pharmaceuticals shares in Q4 2017, an estimated $20K.
  • FNY Partners Fund first reported a position in BioCryst Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • FNY Partners Fund's BioCryst Pharmaceuticals position peaked at $22K in Q2 2017.
  • 116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2017.

Based on FNY Partners Fund's 13F filing for Q4 2017, filed 24 Jan 2018.